Weare pleased to note that persons with mental illness and developmental disability (that is, those with dual diagnoses) are identified as a tertiary care subpopulation by Cochrane and others (1) . With respect to dual diagnosis, our current efforts at Queen's University and in southeastern Ontario include developing a model of community-based care and training those mental health professionals who have a special interest in this subpopulation.
In the absence ofreliable data, we are assuming prevalence rates for mental retardation of 2% for children and 1% for adults. We are also assuming that 10% to 40% of this group have additional mental disorders. Our model ofcare assumes that a mental health team comprising a psychiatrist, a psychiatric social worker, a clinical psychologist, an occupational therapist, and a part-time speech language pathologist is available for every 100 000-150 000 persons. The mental health team oversees care in 3 "generic" services (for example, an emergency department, a mental health clinic, and an acute inpatient unit) and 3 "specialized" services (for example, a community behaviour-management program, a specialized assertive community treatment team, and an extended treatment unit). Community behaviour-management programs are already in place across Ontario; the other specialized programs are innovative but, in our view, totally defensible on the basis of experience in the Netherlands (2) and England (3).
Attracting and training mental health professionals in the field of developmental disabilities is a continuing challenge. Once we have a complete model system established in the Kingston, Ontario, area, we propose to extend our existing training program in psychiatry (4) Can J Psychiatry, Vol 45, June 2000 to include other mental health team professionals. Indeed, it seems desirable to train all professionals together so that they may learn not only about dual diagnosis but also how to function effectively in a team. Evaluation ofthe model services will generate data that can be applied across Ontario and beyond.
We are grateful to Ms Cochrane and her colleagues for identifying this underserved subpopulation in their review of tertiary mental health services.
Bruce D McCreary, MD Philip Burge, MSW Katherine Buell, PhD Kingston, Ontario

Panic Attacks During Discontinuation of Mirtazepine
Dear Editor:
Mirtazepine is a unique antidepressant with effects on multiple receptors. It enhances noradrenergic and serotonergic activity by antagonizing the central presynaptic alpha 2 receptors (1) . It also antagonizes 5HT 2 , 5HT 3 , and histamine HI receptors. Here we report on a patient who developed panic attacks after mirtazepine was discontinued.
Case
The patient is a 51-year-old, married white male with a history of dysthymia, 570 remote marijuana and mescaline abuse, essential hypertension, hypercholesterolemia, and esophageal reflux admitted to the hospital for acute appendicitis. He underwent an appendectomy and umbilical herniorrhaphy. His postoperative course was complicated by delirium that cleared when morphine was discontinued. A psychiatric consultation was requested on day 4 ofadmission because the patient was experiencing panic attacks consisting of palpitations, sweating, hot flushes, and dyspnea. His wife confirmed that he had not previously experienced panic attacks. He reported taking mirtazepine 15 mg daily for several years for depression. Mirtazepine had not been given to him since his admission.
The patient was afebrile and his vital signs were stable. Labs including complete blood count and full metabolic profile were unremarkable.
His current medications included atenolol 25 mg, lansoprazole 30 mg, and atorvastatin 10 mg, all taken orally once each day. He also received intravenous enalapril 1.25 mg every 8 hours, intravenous cefotetan 2 gm every 12 hours, and subcutaneous heparin 5000 U every 12 hours. He received acetaminophen, meperidine, and hydroxyzine as needed.
The patient looked anxious and frequently fanned himselfwith a magazine. A mental status exam revealed that he was alert and oriented to time, person, and place. Neither tremors nor diaphoresis were noted. His insight and judgement were fair. Speech was coherent, and nonpressured. There were no psychotic features, suicidal ideation, or homicidal ideation. The patient's mood was anxious, and his affect full range, though intense at times. There were no gross cognitive deficits.
Mirtazepine 15 mg orally every night was initiated that night. The patient remained free ofpanic attacks the next day and continued to do well. He was discharged 3 days later, free of panic attacks.
Discussion
One prior source has described anxiety and a selective serotonin reuptake inhibitor (SSRI) withdrawal-like syndrome during mirtazepine withdrawal (2) . When mirtazepine is withdrawn, the 5HT 2 , 5HT 3 and HI receptors are no longer antagonized, and synaptic serotonin is suddenly decreased, all ofwhich may induce anxiety. Our patient experienced new-onset panic attacks that resolved with resumption of mirtazepine. We thus feel that the panic attacks were less likely secondary to sepsis, meperidine, or delirium.
Clinicians should alert patients to the potential for anxiety symptoms to appear with abrupt cessation ofmirtazepine. To minimize adverse reactions, more work is needed to clarify the optimal discontinuation rate of mirtazepine Jordan Klesmer, MD Adnan Sarcevic, MD Victor Fomari, MD Manhasset, New York
A Mild Case of Serotonin Syndrome?
Dear Editor:
The use of selective serotonin reuptake inhibitors (SSRIs), alone and in combination, has led to frequent reports in the literature of serotonin hyperstimulation, known as serotonin syndrome. The most common clinical findings associated with this syndrome are delirium-like symptoms, restlessness, myoclonus, hyperreflexia, diaphoresis, shivering, and tremor (1) . Clinical case reports frequently mention a lab finding of increased creatine kinase (CK), in values ranging from just above normal to 50 Letters to the Editor 000 U/L or more. I report a case of elevated CK related to the use ofSSRls, but without significant physical symptoms.
Case Report
At a posttraumatic stress disorder (PTSD) clinic, a 43-year-old man was diagnosed with PTSD, chronic type, and major depressive episode (MDE), severe, without psychotic symptoms. Lab assessment, including a complete blood count, liver and renal functions, and erythrocyte sedimentation rate (ESR) was normal. He was currently taking nefazodone 400 mg daily and trazodone 150 mg daily. These antidepressants were not found to be efficacious and were discontinued. One week after discontinuation, fluvoxamine 50 mg was started. It was titrated to 100 mg 5 days later. The patient took 100 mg daily for 7 days and came to an appointment complaining of cardiac palpitations and mild tightness in his chest. The tightness did not radiate to his jaw or arm, he was not diaphoretic or anxious, and he did not complain of pain. There were no other physical complaints or findings. The patient was not taking any other medication. He had no cardiac history and no other significant medical history. He was sent to the emergency department for assessment. His vital signs were unremarkable, and his lab assessment was normal, with the exception of elevated CK (433 U/L). Fractionation of the CK did not suggest a cardiac origin (normal CK muscle-brain fraction). The fluvoxamine 100 mg was discontinued. The CK normalized over the next 4 days, and the patient was started on citalopram 20 mg daily. His CK was rechecked in 1 week, and again, it was found to be elevated (638 U/L). Fractionation did not support a cardiac origin. The citalopram was discontinued, and after several weeks, his CK had again normalized. A full internal medicine assessment failed to find an explanation other than a drugrelated effect for the transient increase of CK.
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Discussion
A search of the literature did not reveal any similar cases of an isolated increase in CK with mild physical symptoms. There were very few cases of low dose SSRls leading to CK elevations, and all were accompanied by severe physical reactions. One published case was that of an 83-year-old woman with multiple serious medical problems, including an abdominal aortic aneurysm, who was hospitalized with pain, swelling, and tenderness of her upper arms and shoulders, malaise, lethargy, anorexia, and vomiting 3 days after starting fluoxetine 20 mg daily. Her CK was elevated at admission (2951 U/L) and continued to increase despite the discontinuation of the fluoxetine. A biopsy showed acute myositis and extensive muscle infarction. The patient died following partial rupture of an aortic aneurysm and extravasation of a large amount of blood. There was evidence of a myocardial infarction. Because the commencement of the fluoxetine coincided with the development of symptoms and in the absence of another diagnosis, the author concluded that an adverse reaction to fluoxetine had led to vasculitis and secondary muscle necrosis (2).
In another case, an ll-year-old boy taking perphenazine and benztropine was given fluvoxamine for attention-deficit hyperactivity disorder. Within an hour ofhis first dose offluvoxamine (50 mg), he became agitated and unresponsive. In the emergency department he was noted to have autonomic instability, hypothermia, jaw myoclonus, hyperreflexia, and fasciculations. He was moving his limbs "uncontrollably." One day later, his CK was found to be elevated (6500 U/L). He recovered fully after intubation, neuromuscular blockade, and cooling. The author questioned whether a dose of 50 mg was too high for an ll-year-old (3).
The case reported here seems mild by comparison. However, it may represent the relatively benign end of the continuum of serotonin syndrome presentations. Elevated CK is a common clinical finding in cases of serotonin syndrome.
Generally, significant physical findings lead to assessment, and laboratory tests are then requested. In this case, the individual had relatively minor physical findings, and the initial CK was only slightly elevated. However, with a rechallenge of another SSRI, the CK increase was more dramatic, although still relatively minor. Had the SSRI been continued, or had the dose been increased, would this individual have continued on to a "full-blown" serotonin syndrome?
Re: The Impact of Providing Pre-Assessment Information on No-Show Rates
High rates of nonattendance for clinical appointments are a considerable problem in mental health outpatient settings. Studies have documented that 30% to 75% of patients do not keep an initial outpatient appointment (1, 2) , and 20% to 60% fail to attend follow-up appointments for medical or psychological services (3, 4) . Failure to attend represents a substantial drain on health resources because it hinders productive use of clinical time and delays service to individuals more able to use these programs.
In our mental health outpatient clinic, we have evaluated the impact of a relatively simple intervention on no-show rates and inclusion rates for a group cognitive-behavioural therapy program. Prior to this intervention, all referrals to the group were automatically booked for assessment. Over a l-year period, we had a no-show rate of 35% (total referrals = 51), and only 73% of those who The Canadian Joumal of Psychiatry attended the assessment interview were deemed suitable for the group program. Suitability was defined as recognition of a psychosocial component to one's depression and a minimal level of interest in addressing these psychosocial issues through psychotherapy.
To attempt to reduce our no-show rate and improve the ratio ofappropriate candidates to assessments, we mailed an information package to the referee at the time of referral. This package contained a detailed description of the group, ground rules, information to assist individuals in deciding whether they would benefit from participating, and a brief motivational questionnaire. With respect to motivation, for example, we suggested that potential clients do a decisional balance exercise (5) to weigh the advantages and disadvantages of participation in the program. If, after reading the package, participants were interested in being considered for the program, they were required to contact us to set up a screening interview. Using this method, we have to date experienced a striking no-show rate of 0% (total appointments = 28). This improvement was statistically significant when compared with our previous no-show rate of35% (X 2 = 12.14, df 1, P < 0.001). Moreover, our rate ofappropriate candidates to interview grew to 96%, a statistically significant improvement from our initial rate of 73% (X 2 = 6.21, df 1, P < 0.01).
To ensure that we were not overlooking individuals who might benefit from the group, we called those who had failed to contact us to set up an appointment (n = 6). In each case, the individual had appropriately self-selected group noninvolvement, citing such obstacles as conflicting time schedule, no desire to be involved in psychotherapy at present, or even being unaware of the referral prior to receiving the information package in the mail.
In short, introducing a simple prescreening information package and making patients responsible for initiating their own treatment on the basis ofthis material results in considerably more efficient use of clinical time. The savings in clinical time easily offset the minimal cost of Vol 45, No6 photocopying and mailing the prescreening information. It is also our experience that this approach results in patients who are more informed of treatment choices, who take greater responsibility for pursuing treatment, and who are better suited to the therapy. L' abus de substances psychoactives se definit par une consommation reguliere d' alcool ou de drogues qui resulte en des perturbations majeures au niveau social, professionnel ou personnel (1) . La prevalence du probleme d'abus de substances psychoactives est de 50 % chez les personnes atteintes d'une maladie mentale grave (2) comparativement a 16 % dans la population generale (3). La personne schizophrene est particulierement sensible aux effets deleteres de la consommation illicite de ces substances, tant au niveau psychologique que physiologique. L'abus de substances psychoactives a un effet significatif sur l' evolution de la maladie, la sante physique et la qualite de vie du patient schizophrene (4). Cela vient s'ajouter aux multiples repercussions de la maladie elle-rneme, L' abus de substances psychoactives etla schizophrenie n 'interagissent pas seulement de facon additive mais aussi synergique, exacerbant radicalement les consequences de chacun de ces problemes pris independamment (5) . Les competences requises pour atteindre l'ahstinence sont souvent compromises par la schizophrenie, puisque 1'abstinence requiert du patient un haut degre de motivation, un controle face ala tentation et un reseau de soutien social solide et structure. Or, ces elements sont perturbes chez le patient schizophrene, ce qui diminue les chances d'une rehabilitation durable. 11 est reconnu que le schizophrene qui souffre d'un probleme d'abus de substances psychoactives requiert plus souvent une hospitalisation (3,6), qu'il est moins observant du traitement medicamenteux et psychosocial (3, 6, 7) , qu' il repond moins bien au traitement (6,8), qu'il presente une exacerbation de certains effets indesirables lies ala medication, qu'il possede un statut fonctionnel reduit (6) et qu' il presente un risque accru de suicide (3). En general, ce patient utilise done plus de services de soins de sante, et l' augmentation des couts qui en decoule est significative (9) . Etonnamment, l'effet de l'abus de substances psychoactives sur la reponse au traitement pharrnacologique et l' evolution de la maladie est tres peu documente, et peu d' interet a ete porte au potentiel d'interaction entre l'abus de Letters to the Editor substances et la reponse au traitement pharmacologique, malgre les faits mentionnes ci-dessus (10, 11 ) . Peu d' etudes structurees ont montre l'efficacite d'un traitement pharmacologique chez des patients schizophrenes aux prises avec un probleme d'abus de substances psychoactives. En fait, la plupart des essais pharmacologiques ont exclu les patients presentant un problerne d'abus de substances (4) . et ceux qui les ont consideres presentent plusieurs problemes methodologiques, dont la variabilite des substances psychoactives disponibles, l' absence de groupe controle, le nombre reduit de patients et la faible validite des autoquestionnaires utilises pour quantifier la consommation (2, 9) .
Les soins de sante actuels offrent peu de ressources adequates. Le manque de donnees scientifiques accentue grandement le vide therapeutique qui prevaut lorsque coexistent un diagnostic de schizophrenie et un autre d'abus de substances psychoactives. Pourtant, cliniciens et patients y sont regulierement confrontes.
